ClinicalTrials.gg
CompletedNCT04524351Updated Feb 28, 2023Results posted

Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients

A Phase 1/2 interventional study of Posiphen and Placebo in Alzheimer Disease and Parkinson Disease, sponsored by Annovis Bio Inc.. Completed at 13 sites in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2023-02-28.

Sponsored by Annovis Bio Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
792nd of 1,609
75 · median 73
Started
2020
with 103 others
Phase 1/2
67 of 1,940
17 open now
Registered
1,230th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 792nd largest by enrollment of the 1,609 interventional ones that give a count, is one of 104 that started in 2020, is one of 67 in phase 1/2, and was the 1,230th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

Annovis is conducting a clinical study to investigate Posiphen in patients with Early Alzheimer's Disease (AD) and Early Parkinson's Disease (PD). Investigators are looking to recruit 68 patients in two parts of the study. In Part one of the study Investigators will recruit 14 AD and 14 PD patients who will either receive placebo (an inert pill which looks like the study drug) or the study drug Posiphen, both taken daily. In Part two of the study Investigators will recruit 40 PD patients who will receive different strengths of the study drug Posiphen taken daily. Patients will be required to come to the site for 3 face to face visits and have 4 phone calls, tests include but are not limited to, blood and CSF (spinal fluid) sampling, cognitive assessments, clinical examinations and laboratory safety tests. Primarily the Investigators are looking for the safety and tolerability of Posiphen, although Investigators will also evaluate the activity of Posiphen by a number of different biomarkers measuring pathway and target engagements.

Read the detailed description

Part 1 is a study with 14 Early AD and 14 Early PD patients who are randomized to 80 mg of Posiphen or placebo. Participants will undergo a Screening Visit, provide informed consent and be evaluated for eligibility per the inclusion and exclusion criteria. If enrolled, participants will proceed to the randomized treatment portions of the study. Period 1 consists of first-time dosing in clinic with administration of 80 mg of Posiphen or Placebo. Period 2 consists of an at home dosing period of 25±2 days, with daily administration of 80 mg of Posiphen or Placebo. Period 3 will be comprised of a stay at the clinical research unit where the subject will undergo study procedures that include safety assessments (AE and concomitant medication monitoring, 12-lead ECGs, clinical laboratory testing, vital signs assessments, and physical examinations), the last dose of Posiphen or Placebo, and 6 hours of blood and CSF sampling. At the end of blood/CSF sampling, the subjects will need to stay for a minimum of 1 hour of observation but may stay if necessary for observation until the following day (e.g., if the subject has blood/CSF sampling on Day 25, he/she may stay for observation until Day 26). After all end-of-study procedures are complete, the subject will be discharged to home. A 24-hour follow-up call will occur to assess the participants current condition and if there are any additional adverse events to report.

After completion of Part 1 of the study, the plasma and CSF samples will be analyzed for the biomarkers to determine if changes are needed to the biomarkers to be measured in Part 2. Since the conduct of the study in Part 2 will be identical to the conduct of the study in Part 1, recruitment will continue uninterrupted. The only potential change between Part 1 and Part 2 are the biomarkers to be measured.

Part 2 is a study with 40 Early PD patients, 10 patients each who are randomized to one of 4 treatment conditions of Posiphen (5 mg, 10 mg, 20 mg, or 40 mg). Participants will undergo a Screening Visit, provide informed consent and be evaluated for eligibility per the inclusion and exclusion criteria. If enrolled, participants will proceed to the randomized treatment portions of the study. Period 1 consists of first-time dosing in clinic with administration of 5, 10, 20, or 40mg of Posiphen. Period 2 consists of an at home dosing period of 25±2 days, with daily administration of 5, 10, 20, or 40mg of Posiphen. Period 3 will be comprised of a stay at the clinical research unit where the subject will undergo study procedures that include safety assessments (AE and concomitant medication monitoring, 12-lead ECGs, clinical laboratory testing, vital signs assessments, and physical examinations), the last dose of Posiphen or Placebo, and 6 hours of blood and CSF sampling. At the end of blood/CSF sampling, the subject will need to stay for a minimum of 1 hour of observation but may stay if necessary for observation until the following day (e.g., if the subject has blood/CSF sampling on Day 25, he/she may stay for observation until Day 26). After all end-of-study procedures are complete, the subject will be discharged to home. A 24-hour follow-up call will occur to assess the participant's current condition and if there are any additional adverse events to report.

03

Conditions studied

  • Alzheimer Disease
  • Parkinson Disease

Keywords

  • Safety
  • Tolerability
  • Pharmacokinetics
  • Pharmacodynamics
  • Neurotoxic proteins
  • Neurotransmitters
  • Amyloid Precursor Proteins
  • Inflammatory factors
  • Synaptic factors
  • CSF
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet the following criteria:

  1. Male or female aged 45 years and over.
  2. Female participants must be of non- or for at least 2 consecutive years or surgically sterile (bilateral tubal ligation, hysterectomy or bilateral oophorectomy) for at least 6 months prior to screening.
  3. Female participants will be given a urine pregnancy test at the screening visit for which they should test negative.
  4. A) AD - CDR = 0.5 or 1. B) PD - Hoehn \& Yahr ≤ 4; PD criteria by MDS-UPDRS.
  5. A) AD score between the range of 18 to 28. B) PD MMSE score between the range of 18 to 30.
  6. General cognition and functional performance sufficiently preserved that the subject can provide written .
  7. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.
  8. MRI scan within the 12 months prior to screening without evidence of infection, infarction, or other focal lesions and without clinical symptoms suggestive of intervening neurological disease. Lacunes that are not believed to contribute to the subject's cognitive impairment are permissible. If there is no MRI available within a 12-month timeframe, then an MRI must be performed as part of the screening procedures for eligibility.
  9. Stability of permitted medications prior to screening.

    1. Stable for at least 12 weeks: Cholinesterase inhibitors and/or memantine medication
    2. Stable for at least 4 weeks:

    i. Anti-parkinsonian medication ii. Anticonvulsant medications used for epilepsy or mood stabilization; neuropathic pain indications iii. Mood-stabilizing psychotropic agents, including, but not limited to, lithium.

  10. Adequate visual and hearing ability (physical ability to perform all the study assessments).
  11. Good general health with no disease expected to interfere with the study.
  12. Subjects previously exposed to Posiphen may be included in the study.

Exclusion criteria

Exclusion Criteria

Subjects meeting any of the following criteria must not be included in the study:

  1. Has a history of a psychiatric disorder such as schizophrenia, bipolar disorder or major depression according to the criteria of the most current version of the (DSM). Mild depression or history of depression that is stable on treatment with a SSRI or SNRI medication at a stable dose is acceptable.
  2. History of a seizure disorder.
  3. Has a history or current evidence of long syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450ms, or torsades de pointes.
  4. Has bradycardia (\<50 bpm) or tachycardia (>100 bpm) on the at screening.
  5. Has uncontrolled Type-1 or Type-2 diabetes . A Subject with levels up to 7.5% can be enrolled if the investigator believes the subject's diabetes is under control.
  6. Has renal or hepatic impairment.
  7. Has any clinically significant abnormal laboratory values. Subjects with liver function tests ( [AST] or alanine aminotransferase [ALT]) greater than twice the will be excluded.
  8. Is at imminent risk of self-harm, based on clinical interview and responses on the C SSRS, or of harm to others in the opinion of the Investigators. Subjects must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g. positive response to Items 4 or 5 in assessment of suicidal ideation on the C SSRS) in the past 2 months, or suicidal behavior in the past 6 months.
  9. Has four or more signal hypointensities on T2*-weighted gradient recalled echo magnetic resonance sequences that are thought to represent hemosiderin deposits including microhemorrhages and superficial siderosis or evidence of acute or sub-acute micro or microhemorrhage as noted on the MRI scan.
  10. Has cancer or has had a malignant tumor within the past year, except patients who underwent potentially curative therapy with no evidence of recurrence. (Patients with stable untreated prostate cancer or skin cancers are not excluded).
  11. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.
  12. Participation in another clinical trial with an agent and have taken at least one dose of study medication, unless unblinded on placebo, within 60 days prior to the start of screening. (The end of a previous investigational trial is the date the last dose of an investigational agent was taken), or five half-lives of the investigational drug, whichever is greater.
  13. Subjects with infection or inflammation of the skin or skin disease at or in proximity to the lumbar puncture site.
  14. History of lumbar spine surgery or chronic low back pain (CLBP).
  15. Subjects with learning disability or developmental delay.
  16. Subjects whom the site PI deems to be otherwise ineligible.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Active comparator
    Posiphen, 80mg (Parkinson's Participants)

    Posiphen Oral Capsule, 80mg, taken once per day for 25±2 days.

    Drug: Posiphen

  • Active comparator
    Posiphen, 40mg (Parkinson's Participants)

    Posiphen Oral Capsule, 40mg, taken once per day for 25±2 days.

    Drug: Posiphen

  • Active comparator
    Posiphen, 20mg (Parkinson's Participants)

    Posiphen Oral Capsule, 20mg, taken once per day for 25±2 days.

    Drug: Posiphen

  • Active comparator
    Posiphen, 10mg (Parkinson's Participants)

    Posiphen Oral Capsule, 10mg, taken once per day for 25±2 days.

    Drug: Posiphen

  • Active comparator
    Posiphen, 5mg (Parkinson's Participants)

    Posiphen Oral Capsule, 5mg, taken once per day for 25±2 days.

    Drug: Posiphen

  • Placebo comparator
    Placebo (Parkinson's Participants)

    Placebo Oral Capsule, taken once per day for 25±2 days.

    Drug: Placebo

  • Placebo comparator
    Placebo (Alzheimer's Participants)

    Placebo Oral Capsule, taken once per day for 25±2 days.

    Drug: Placebo

  • Active comparator
    Posiphen, 80mg (Alzheimer's Participants)

    Posiphen Oral Capsule, 80mg, taken once per day for 25±2 days.

    Drug: Posiphen

Interventions

  • Solid oral dosage form, capsule

  • DrugPlacebo

    Solid oral dosage form, capsule

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events

    Percent of patients with AEs in the Posiphen treatment arms compared to the Placebo group

    Time frame: 25±2 days

Secondary outcomes

  1. Concentration of Posiphen in Plasma

    Maximum Plasma Concentration (Cmax) of Posiphen reported as ng/mL.

    Time frame: Samples collected over a 6 hour timeframe

Other outcomes

  1. Change in Abeta42/Abeta40 Ratio

    Biomarker related to neurotoxic protein cascade measured in patient sample

    Time frame: Baseline to 25±2 days

  2. Changes in Functional Impairment

    Functional impairment will be evaluated using the Clinical Dementia Rating (CDR) scale (Berg1988) for AD.

    Time frame: Baseline to 25±2 days

  3. Changes in Functional Impairment

    Functional impairment will be evaluated using the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scale (Goetz 2008) for those with PD.

    Time frame: Baseline to 25±2 days

  4. Changes in Cognition

    For both populations, the Mini-Mental State Examination (MMSE) scale (Folstein 1975) will be administered as a global measure of cognition.

    Time frame: Baseline to 25±2 days

  5. Changes in Cognition

    For both populations, the Coding subtest from the Weschler Adult Intelligence Scales, 4th edition (WAIS-IV) will serve as a sensitive measure of CNS dysfunction.

    Time frame: Baseline to 25±2 days

  6. Changes in Cognition

    The subjects with AD will also be administered the The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale (Schafer 2012).

    Time frame: Baseline to 25±2 days

07

Results

Posted Feb 28, 2023

Participant flow

Participant flow — Overall Study
MilestonePosiphen, 80mg (Parkinson's Participants)Posiphen, 40mg (Parkinson's Participants)Posiphen, 20mg (Parkinson's Participants)Posiphen, 10mg (Parkinson's Participants)Posiphen, 5mg (Parkinson's Participants)Placebo (Parkinson's Participants)Placebo (Alzheimer's Participants)Posiphen, 80mg (Alzheimer's Participants)
Started10101110125610
Completed99119115510
Not completed11011010

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events

Percent of patients with AEs in the Posiphen treatment arms compared to the Placebo group

Time frame:
25±2 days
Reported as:
Count of participants · Participants
Percentage of Participants With Treatment-Emergent Adverse Events
ParticipantsPosiphen, 80mg (Parkinson's Participants)Posiphen, 40mg (Parkinson's Participants)Posiphen, 20mg (Parkinson's Participants)Posiphen, 10mg (Parkinson's Participants)Posiphen, 5mg (Parkinson's Participants)Placebo (Parkinson's Participants)Placebo (Alzheimer's Participants)Posiphen, 80mg (Alzheimer's Participants)
Percentage of Participants With Treatment-Emergent Adverse Events35461335
SecondaryConcentration of Posiphen in Plasma

Maximum Plasma Concentration (Cmax) of Posiphen reported as ng/mL.

Time frame:
Samples collected over a 6 hour timeframe
Reported as:
Mean · ng/mL
Concentration of Posiphen in Plasma
ng/mLPosiphen, 80mg (Parkinson's Participants)Posiphen, 40mg (Parkinson's Participants)Posiphen, 20mg (Parkinson's Participants)Posiphen, 10mg (Parkinson's Participants)Posiphen, 5mg (Parkinson's Participants)Placebo (Parkinson's Participants)Placebo (Alzheimer's Participants)Posiphen, 80mg (Alzheimer's Participants)
Concentration of Posiphen in Plasma94.9 ± 33.440.2 ± 19.715.3 ± 21.62.0 ± 1.40.4 ± 0.3——112.3 ± 49.3
Other pre-specifiedChange in Abeta42/Abeta40 Ratio

Biomarker related to neurotoxic protein cascade measured in patient sample

Time frame:
Baseline to 25±2 days

Results for this outcome have not been posted.

Other pre-specifiedChanges in Functional Impairment

Functional impairment will be evaluated using the Clinical Dementia Rating (CDR) scale (Berg1988) for AD.

Time frame:
Baseline to 25±2 days

Results for this outcome have not been posted.

Other pre-specifiedChanges in Functional Impairment

Functional impairment will be evaluated using the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scale (Goetz 2008) for those with PD.

Time frame:
Baseline to 25±2 days

Results for this outcome have not been posted.

Other pre-specifiedChanges in Cognition

For both populations, the Mini-Mental State Examination (MMSE) scale (Folstein 1975) will be administered as a global measure of cognition.

Time frame:
Baseline to 25±2 days

Results for this outcome have not been posted.

Other pre-specifiedChanges in Cognition

For both populations, the Coding subtest from the Weschler Adult Intelligence Scales, 4th edition (WAIS-IV) will serve as a sensitive measure of CNS dysfunction.

Time frame:
Baseline to 25±2 days

Results for this outcome have not been posted.

Other pre-specifiedChanges in Cognition

The subjects with AD will also be administered the The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale (Schafer 2012).

Time frame:
Baseline to 25±2 days

Results for this outcome have not been posted.

Adverse events

Collected over 25±2 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Posiphen, 80mg (Parkinson's Participants)0/10 (0%)0/10 (0%)3/10 (30%)
Posiphen, 40mg (Parkinson's Participants)0/10 (0%)0/10 (0%)5/10 (50%)
Posiphen, 20mg (Parkinson's Participants)0/11 (0%)0/11 (0%)4/11 (36.4%)
Posiphen, 10mg (Parkinson's Participants)0/10 (0%)0/10 (0%)6/10 (60%)
Posiphen, 5mg (Parkinson's Participants)0/12 (0%)0/12 (0%)1/12 (8.3%)
Placebo (Parkinson's Participants)0/5 (0%)0/5 (0%)3/5 (60%)
Placebo (Alzheimer's Participants)0/6 (0%)0/6 (0%)3/6 (50%)
Posiphen, 80mg (Alzheimer's Participants)0/10 (0%)0/10 (0%)5/10 (50%)
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPosiphen, 80mg (Parkinson's Participants)Posiphen, 40mg (Parkinson's Participants)Posiphen, 20mg (Parkinson's Participants)Posiphen, 10mg (Parkinson's Participants)Posiphen, 5mg (Parkinson's Participants)Placebo (Parkinson's Participants)Placebo (Alzheimer's Participants)Posiphen, 80mg (Alzheimer's Participants)
back painMusculoskeletal and connective tissue disorders0/101/100/111/100/122/51/61/10
headacheNervous system disorders0/101/103/114/100/121/50/62/10
puncture site painGeneral disorders0/100/100/111/100/120/52/61/10
dizzinessNervous system disorders0/100/100/110/101/121/50/60/10
pain in extremityMusculoskeletal and connective tissue disorders0/100/100/111/100/121/50/60/10
fatigueGeneral disorders0/100/102/111/100/120/50/60/10
aspartate aminotransferase increasedInvestigations0/100/100/110/100/120/51/60/10
electrocardiogram QT prolongationInvestigations0/100/100/110/100/120/50/61/10
liver function test abnormalInvestigations0/100/100/110/100/120/50/61/10
cystitisInfections and infestations0/100/100/110/100/120/50/61/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Posiphen, 80mg (Parkinson's Participants)Posiphen, 40mg (Parkinson's Participants)Posiphen, 20mg (Parkinson's Participants)Posiphen, 10mg (Parkinson's Participants)Posiphen, 5mg (Parkinson's Participants)Placebo (Parkinson's Participants)Placebo (Alzheimer's Participants)Posiphen, 80mg (Alzheimer's Participants)Total
Mean65.0 ± 9.3162.5 ± 6.7469.8 ± 10.9362.0 ± 9.9367.2 ± 6.9475.4 ± 3.1368.0 ± 6.8772.8 ± 6.3467.3 ± 8.84
Sex: Female, Male
Sex: Female, Male(Participants)Posiphen, 80mg (Parkinson's Participants)Posiphen, 40mg (Parkinson's Participants)Posiphen, 20mg (Parkinson's Participants)Posiphen, 10mg (Parkinson's Participants)Posiphen, 5mg (Parkinson's Participants)Placebo (Parkinson's Participants)Placebo (Alzheimer's Participants)Posiphen, 80mg (Alzheimer's Participants)Total
Female2233223825
Male88871033249
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Posiphen, 80mg (Parkinson's Participants)Posiphen, 40mg (Parkinson's Participants)Posiphen, 20mg (Parkinson's Participants)Posiphen, 10mg (Parkinson's Participants)Posiphen, 5mg (Parkinson's Participants)Placebo (Parkinson's Participants)Placebo (Alzheimer's Participants)Posiphen, 80mg (Alzheimer's Participants)Total
Hispanic or Latino0052324521
Not Hispanic or Latino101068932553
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Posiphen, 80mg (Parkinson's Participants)Posiphen, 40mg (Parkinson's Participants)Posiphen, 20mg (Parkinson's Participants)Posiphen, 10mg (Parkinson's Participants)Posiphen, 5mg (Parkinson's Participants)Placebo (Parkinson's Participants)Placebo (Alzheimer's Participants)Posiphen, 80mg (Alzheimer's Participants)Total
American Indian or Alaska Native000000000
Asian001000113
Native Hawaiian or Other Pacific Islander000000011
Black or African American001000102
White10109101254868
More than one race000000000
Unknown or Not Reported000000000
Region of Enrollment
Region of Enrollment(participants)Posiphen, 80mg (Parkinson's Participants)Posiphen, 40mg (Parkinson's Participants)Posiphen, 20mg (Parkinson's Participants)Posiphen, 10mg (Parkinson's Participants)Posiphen, 5mg (Parkinson's Participants)Placebo (Parkinson's Participants)Placebo (Alzheimer's Participants)Posiphen, 80mg (Alzheimer's Participants)Total
United States1010111012561074
08

Study locations

13 sites
  • New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • DeLand Clinical Research Unit
    DeLand, Florida 32720, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Homestead Associates in Research
    Miami, Florida 33032, United States
  • Ezy Medical Research Co.
    Miami, Florida 33175, United States
  • Conquest Research LLC
    Winter Park, Florida 32789, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • Hawaii Pacific Neuroscience
    Honolulu, Hawaii 96817, United States
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
  • North Suffolk Neurology, PC
    Port Jefferson Station, New York 11776, United States
  • Penn Medicine, Department of Neurology, U of PA
    Philadelphia, Pennsylvania 19107, United States
  • University of Texas Health Science Center
    San Antonio, Texas 78229, United States
  • Aspen Clinical Research LLC
    Orem, Utah 84058, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Aug 2021, 12 months.

Results were first posted in Feb 2023, 1 year 6 months after primary completion.

Of 62 phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Aug 24, 2020
StartActual
Aug 14, 2020
Primary completionActual
Aug 16, 2021
CompletionActual
Jan 31, 2022
Results first posted
Feb 28, 2023
Last update
Feb 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04524351
Lead sponsor
Annovis Bio Inc.
Collaborators
Parexel
Responsible party
Sponsor
First posted
Aug 24, 2020
Start date
Aug 14, 2020
Primary completion
Aug 16, 2021
Completion
Jan 31, 2022
Results posted
Feb 28, 2023
Last update
Feb 28, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Buntanetap

Start the discussion